- $1.19m
- $8.47m
- $6.77m
- 26
- 78
- 27
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.17 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.33 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -266.14% | ||
| Return on Equity | -206.77% | ||
| Operating Margin | -778.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 14.51 | 79.04 | 122.65 | 34.98 | 6.77 | 21.36 | 41.69 | -7.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +200.2 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Directors
- Ted Karkus CHM (61)
- Monica Brady CFO (43)
- Jason Karkus COO
- Alice Lioi COO
- Sergio Miralles CIN
- Sam Beeler OTH
- Jason Barr IND (41)
- Louis Gleckel IND (65)
- Warren Hirsch IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- June 18th, 2015
- Public Since
- January 16th, 1984
- No. of Shareholders
- 147
- No. of Employees
- 96
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 6,021,624
- Address
- 711 STEWART AVE, SUITE 200, GARDEN CITY, NEW YORK, 11530
- Web
- https://www.prophaselabs.com/
- Phone
- +1 2153450919
- Auditors
- Fruci & Associates II, PLLC
Similar to PRPH
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
Aesthetic Medical International Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 21:46 UTC, shares in Prophase Labs are trading at $0.20. This share price information is delayed by 15 minutes.
Shares in Prophase Labs last closed at $0.20 and the price had moved by -96.64% over the past 365 days. In terms of relative price strength the Prophase Labs share price has underperformed the S&P500 Index by -97.28% over the past year.
The overall consensus recommendation for Prophase Labs is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreProphase Labs does not currently pay a dividend.
Prophase Labs does not currently pay a dividend.
Prophase Labs does not currently pay a dividend.
To buy shares in Prophase Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.20, shares in Prophase Labs had a market capitalisation of $1.19m.
Here are the trading details for Prophase Labs:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PRPH
Based on an overall assessment of its quality, value and momentum Prophase Labs is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Prophase Labs is $16.00. That is 7980.81% above the last closing price of $0.20.
Analysts covering Prophase Labs currently have a consensus Earnings Per Share (EPS) forecast of -$0.56 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prophase Labs. Over the past six months, its share price has underperformed the S&P500 Index by -95.8%.
As of the last closing price of $0.20, shares in Prophase Labs were trading -93.95% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Prophase Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Prophase Labs' management team is headed by:
- Ted Karkus - CHM
- Monica Brady - CFO
- Jason Karkus - COO
- Alice Lioi - COO
- Sergio Miralles - CIN
- Sam Beeler - OTH
- Jason Barr - IND
- Louis Gleckel - IND
- Warren Hirsch - IND